Australian Gonococcal Surveillance Program, 1 January to 31 March 2024

Monica M Lahra; Sebastiaan van Hal; Sonya Natasha Hutabarat; Tiffany R Hogan

doi:10.33321/cdi.2025.49.001

Australian Gonococcal Surveillance Program, 1 January to 31 March 2024

Commun Dis Intell (2018). 2025 Jan 22:49. doi: 10.33321/cdi.2025.49.001.

Authors

Monica M Lahra^{1

2}, Sebastiaan van Hal³, Sonya Natasha Hutabarat⁴, Tiffany R Hogan¹

Affiliations

¹ The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia.
² The School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia.
³ Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
⁴ Department of Microbiology, NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.

PMID: 39837612
DOI: 10.33321/cdi.2025.49.001

Abstract

The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 January to 31 March 2024.

MeSH terms

Anti-Bacterial Agents* / pharmacology
Australia / epidemiology
Drug Resistance, Bacterial*
Gonorrhea* / drug therapy
Gonorrhea* / epidemiology
Gonorrhea* / microbiology
Humans
Microbial Sensitivity Tests*
Neisseria gonorrhoeae* / drug effects
Population Surveillance

Substances

Anti-Bacterial Agents